Risk factors for barrett's esophagus among patients with gastroesophageal reflux disease: A community clinic-based case-control study

American Journal of Gastroenterology

Volumn 104, Issue 4, 2009, Pages 834-842

  Edelstein, Zoe R ^a,b   Bronner, Mary P ^c   Rosen, Sheldon N ^d   Vaughan, Thomas L ^a,b,e  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d CENTER FOR HEALTH STUDIES   (United States)

^e Program in Epidemiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; ASIAN; BARRETT ESOPHAGUS; BODY MASS; CASE CONTROL STUDY; CIGARETTE SMOKING; COLUMNAR EPITHELIUM; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE DURATION; ESOPHAGEAL ADENOCARCINOMA; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; INDEPENDENT VARIABLE; INTESTINE METAPLASIA; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; THORAX PAIN; WAIST HIP RATIO; AGE DISTRIBUTION; COMPLICATION; CONFIDENCE INTERVAL; INTESTINE MUCOSA; MIDDLE AGED; PATHOLOGY; PRECANCER; RETROSPECTIVE STUDY; RISK; SEX RATIO; SMOKING; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; BODY MASS INDEX; CONFIDENCE INTERVALS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; ODDS RATIO; PRECANCEROUS CONDITIONS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX DISTRIBUTION; SMOKING; WASHINGTON; YOUNG ADULT;

EID: 65449181647     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.137     Document Type: Article

References (56)

1. Dent J, El-Serag HB, Wallander MA et al. Epidemiology of gasrooesophageal reflux disease: a systematic review. Gut 2005;54:710-7.
2. Heikkinen TJ, Haukipuro K, Koivukangas P et al. Comparison of costs between laparoscopic and open Nissen fundoplication: a prospec̈ve randomized study with a 3-month followup. I Am Coil Surg 1999;188: 368-76.
3. Myrvold HE, Lundell L, Miettinen P et al. The cost of long term therapy for gastro-oesophageal reflux disease: a randomised trial comparing omeprazole and open antireflux surgery. Gu 2001;49:488-94.
4. Sandler RS, Everhart JE, Donowitz M et al. The burden of selected digestive diseases in the United States. Gastroenterolog 2002;122:1500-11.
5. Eloubeidi MA, Provenzale D. Hea1th-re1aed quality of life and severfty of symptoms in patients wkh Barreffs esophagus and gasroesophagea1 reflux disease patients without Barrett's esophagus. Am I Gastroenterol 2000;95:1881-7.
6. Revicki DA, Wood M, Maon PN et al. The impact of gasroesophagea1 reflux disease on health-related qualit) of life. Am J Med 1998;104: 252-8.
7. Farrow DC, Vaughan TL, Sweeney C et al. Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Conro1 2000;11:231-8.
8. Lagergren J, Bergstrom R, Lindgren A et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
9. Falk GW. Barrel's esophagus. Gasroentero1ogy 2002; 122:1569-91.
10. Jankowski JA, Harrison RF, Perry I et al. Barrett's metaplasia. Lancet 2000;356;2079-85.
11. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett s esophagus. Am J Gastroenterol 2002;97: 1888-95.
12. Sampliner RE. Epidemiology, pathophysiology, and treatment of Barrett's esophagus: reducing mortality from esophageal adenocarcinoma. Med Clin North Am 2005;89:293-312.
13. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-53.
14. Jeon J, Luebeck E, Moolgavkar S. Age effects and temporal trends in adenocarcinoma of the esophagus and gastric cardia (United States). Cancer Causes and Control 2006;17:971-81.
15. Holmes RS, Vaughan TL. Epidemiology and pathogensis of esphogeal cancer. J Natl Cancer Inst 2007;17:2-9.
16. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarethoma incidence. I Natl Cancer Inst 2005;97:142-6.
17. Corley DA, Kubo A, Levin TR et al., Abdominal obesity and body mass index as risk factors for Barrett's esophagos. Gastroenterology 2007;133: 34-41.
18. Edelstein ZR, Farrow DC, Bronner MP et al. Central adiposity and risk of Barrett's esophagus. Gastroenterology 2007;133:403-11.
19. Smith KJ, O'Brien SM, Smilhers BM et al. Interactions among smoking, obesity, and symptoms of acid reflux in Barrett's esophagus. Cancer EpidemiolBiomarkers Prey 2005;14 (11 Part 1): 2481-6.
20. Kerkbof M, Sleyerberg EW, Kuslers JG et al. Predicting presence of intestinal metaplasia and dysplasia in columnar-lined esophagus: a multivariate analysis. Endoscopy 2007;39:772-8.
21. Wang K, Samplther R. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenlerol 2008;103:788-97.
22. Mueller J, Werner M, Slolle M. Barrett's esophagus: histopaihologic definitions and diagnostic criteria. World J Surg 2004;28:148-54.
23. Sharma P, Sampliner RE. Short segment Barrett's esophagus and intestinal metaplasia of the cardia-it's not all symantics!i!. Am J Gaslroenlerol 1998;93:2303-4.
24. Spechler SJ. Short and ultrashort Barrett's esophagus-what does ii mean? Semin Gastrointest Dis 1997;8:59-67.
25. Lohman T, Roche AF, Martorell RI. Anthropometric Standardization Reference Manual. Human Kinetics Books: Cbicago, IL, 1988.
26. Midolo PD, Lambert JR, Russell EG et al. A practical single sample dry latex agglutination test for Helicobacter pylon antibody detection. J Clin Pathol 1995;48:969-71.
27. StataCorp. Stata/SE 9.0 for Windows. StataCorp: College Station, TX, 2005.
28. Cameron AT, Zinsmeister AR, Ballard DJ et al. Prevalence of columnar- lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 1990;99:918-22.
29. Ford AC, Forman D, Reynolds PD et al. Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus. Am Epidemiol 2005;162:454-60.
30. Johansson J, Hakansson HO, MelIblom L et al. Risk factors for Barrett's oesophagus: a population-based approach. Scand I Gastroenlerol 2007;42:148-56.
31. Lieberman D, Fennerty MB, Morris CD et al. Endoscopic evaluation of patients with dyspepsia: results from the national endoscopic data reposstor)c Gastroenlerology 2004;l 27:1067-75.
32. Cook MB, Wild CP, Furman D. A systematic review and mela-analysis of the sex ratio fur Barrett's esophagus, erosive reflux disease, and nunerosix e rellux disease. Am J Epidemiol 2005; 162:1050-61.
33. Hirola WK, Loughney TM, Lazas DJ et al. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterolog) 1999;1 16:277-85.
34. el-Serag H, Sonnenberg A. Associations between different forms of gastronesophageal reflux disease. Gui 1997;41:594-9.
35. Fass R. Erosive esuphagitis and nonerusive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol 2007;41:131-7.
36. Abrams JA, Fields 5, Lightdale CT et al. Racial and ethnic disparities in the prevalence of Barrett's esophagus among patients who undergo upper endoscopy. Clin Gastroenterol Hepatol 2008;6:30-4.
37. Lam KD, Phan JT, Garcia RT et al. Low Proportion of Barrett's Esophagus in Asian Americans. Am J Gastroenterol 2008;103:1625-30.
38. El-Serag HB, Kvapil P, Hacken-Bitar I et al. Abdominal obesity and the risk of Barrett's esophagus. Am I Gastroenternl 2005;l00:2151-6.
39. Blaser MJ, Atherton JC. Helicobacter p)lori persistence: biology and disease. J Clin Invest 2004;113:321-33.
40. El-Serag H, Graham D, Rabeneck L et al. Prevalence and determinants of histological abnormalities of the gastric cardia in volunteers. Scand Gastroenterol 2007;42:l158-66.
41. Trayhurn P, Bing C, Wood IS. Adipose tissue and adipokines-energy regulation from the human perspective. J Nuir 2006;136 (7 Suppl): 1935S-9S.
42. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. JAm Coll Cardiol 2006;47:1093-100.
43. Considine RV, Sinha MK, Heiman ML et al. Serum immunoreacliveleptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-5.
44. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000;21:697-738.
45. Xu H, Barnes GT, Yang Q et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821-30.
46. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-91.
47. Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic review. Br J Cancer 2006;94:1221-5.
48. Wang Y, Lam KS, Xu JY et al. Adipnnectin inhibits cell proliferation by interacting wish several growth factors in an nlignmerizalinn-dependenl manner. J Biol Chem 2005;280:18341-7.
49. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorlicnid. I Clin Endncrinol Melab 1998;83: 847-50.
50. Higdon TV, Frei B. Obesity and oxidative stress: a direct link to CVD? Arterioscler Thromb Vase Biul 2003;23:365-7.
51. Otero M, Lagn R, Lago F et al. Leptin, from fat to inflammation: old questions and new insights. FEBS Lett 2005;579:295-301.
52. Tsukui 5, Kanda T, Nara RI et al. Moderate-intensity regular exercise decreases serum tumor necrosis factor-alpha and HbAlc levels in healthy women. Int T Obes Relat Metab Disnrd 2000;24:1207-1l.
53. Zahurska-Markiewicz B, Januwska J, Olszanecka-Glinianouicz M et al. Serum concentrations of TNF-alpha and soluble TNF-alpha receptors in obesftyc Int T Obes Relat Metab Disord 2000;24:1392-5.
54. Somasundar P, McFadden DW Hileman SM et al. Leptin is a growth factor in cancer. I Surg Res 2004;116:337-49.
55. Kendall BJ, Macdonald GA, Hayward NK et al. Leptin and the risk of Barrett's oesophagus. Gut 2008;57:448-54.
56. Malfertheiner p, Peitz U. The interplay between Helicobacter pylon, gastro-nesophageal refiux disease, and intestinal metaplasia. Gut 2005;54 (Suppl 1): i13-20.